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Objectives: The Joint United Nations Programme on HIV/AIDS (UNAIDS) 90–90–90
and other cross-sectional metrics can lead to potentially counterintuitive conclusions
when used to evaluate health systems’ performance. This study demonstrates how time
and population dynamics impact UNAIDS 90–90–90 metrics in comparison with a
longitudinal analogue.
Design: A simplified simulation representing a hypothetical population was used to
estimate and compare inference from UNAIDS 90–90–90 metrics and longitudinal
metrics based on Kaplan–Meier-estimated 2-year probability of transition between
stages.
Methods: We simulated a large cohort over 15 years. Everyone started out at risk for
HIV, and then transitioned through the HIV care continuum based on fixed daily
probabilities of acquiring HIV, learning status, entering care, initiating antiretroviral
therapy (ART), and becoming virally suppressed, or dying. We varied the probability of
ART initiation over three five-year periods (low, high, and low). We repeated the
simulation with an increased probability of death.
Results: The cross-sectional probability of being on ART among persons who were
diagnosed responded relatively slowly to changes in the rate of ART initiation. Increases
in ART initiation rates caused apparent declines in the cross-sectional probability of
being virally suppressed among persons who had initiated ART, despite no changes in
the rate of viral suppression. In some cases, higher mortality resulted in the cross-
sectional metrics implying improved healthcare system performance. The longitudinal
continuum was robust to these issues.
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Conclusion: The UNAIDS 90–90–90 care continuum may lead to incorrect inference
when used to evaluate health systems performance. We recommend that evaluation of
HIV care delivery include longitudinal care continuum metrics wherever possible.
Copyright  2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
The treatment continuum or cascade of care divides the
process by which individuals and populations progress
from HIV acquisition through ongoing viral suppression
into discrete steps [1]. Cascades are typically represented
as the number or proportion of people in a population at a
given cross-section in time. The Joint United Nations
Programme on HIV/AIDS (UNAIDS) 90–90–90
targets are ubiquitous continuum of care goals for
monitoring and evaluating the global HIV response.
Achieving high or low proportions in any target is
generally attributed to successes or gaps in healthcare
system specific to transitioning from the denominator
state to the numerator [2]. The targets state that 90% of all
people living with HIV should know their HIV status,
90% of all people with diagnosed HIV infection should
receive sustained antiretroviral therapy (ART), and 90%
of all people receiving ART should have viral suppression
in order to end the AIDS epidemic [3].
However, because they rely on a cross-sectional
framework to describe dynamic, longitudinal, and
interrelated processes, the UNAIDS 90–90–90 metrics
may yield misleading inference about health systems
performance [4,5]. Health systems changes can have
counterintuitive impacts on cross-sectional performance
metrics, potentially resulting in misinterpretation, poor
policy and resource allocation decisions, and adverse
mortality and morbidity outcomes.
Longitudinal continuums have been emerging as an
approach to address these issues, which have been used to
evaluate heath systems performance in a variety of settings
and formulations [1,6–15]. While cross-sectional con-
tinuums yield a snapshot of the current state of a system,
longitudinal continuums describe movement between
states over time, conceptually analogous to prevalence and
incidence, respectively. One longitudinal cascade
approach is the ‘HIV testing and treatment cascade,’
[16] which measures person time from the one common
entry event, such as HIV infection or clinical diagnosis, to
all subsequent stages [10,17]. A second approach uses a
stage-by-stage method, where each stage depends on
completion of the previous, analogous to the UNAIDS
90–90–90 targets [4]. In the current article, we focus on
the latter approach to conduct a side-by-side comparison
of the UNAIDS 90–90–90 metrics against a longitudinal
analogue.
The mechanisms by which the UNAIDS 90–90–90 and
other cross-sectional metrics may yield misleading
inference about health systems performance – and
how longitudinal approaches may resolve these issues –
are largely undocumented and poorly understood. We
focus on four issues with the UNAIDS 90–90–90
metrics: they are relatively slow to respond to emerging
conditions; they can change even when there is no
underlying change in system performance; they are
subject to unintuitive and complicated between-stage
interactions; and they are counter intuitively impacted
by mortality.
We designed this study to examine and demonstrate how
summarizing a longitudinal, interrelated set of dynamic
processes using cross-sectional proportions can impact the
UNAIDS 90–90–90 metrics in unintuitive ways. We also
demonstrate how longitudinal approaches may provide
more direct, robust, and reliable metrics for evaluating
HIV systems performance.
Methods
We developed a stochastic, individual-based simulation
model to represent a stylized introduction and expansion
of ART, changing only the ART initiation rate over time.
We simulate two scenarios: one with relatively low
mortality rates (baseline) and one with relatively high
mortality rates (5 the baseline) sustained over the entire
simulated 15-year period. We compared cross-sectional
and longitudinal continuum metrics both within and
between the simulated periods and scenarios to assess
their responses to the changing ART and mortality
conditions.
Simulation structure and baseline parameters
The simulation was based on a Markov chain process,
modelled after the ‘HIV States and Transitions Frame-
work’ [18]. The model classifies each individual into one
of the following ordinal states at each point in time: at risk
for HIV, living with HIV, knows status, in care, on ART,
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virally suppressed, or dead. The simulations begin with
every person being at risk for HIV. At daily time steps,
each simulated person in the model may remain in the
same state, transition to the next state, or die, according to
defined probabilities that are evaluated stochastically for
each person at each time step. Transition rates are assumed
to be identical for all persons for any given transition. For
simplicity, the model did not include any skipping of
stages, ‘side door’ [19] entry into the continuum,
reversion to previous stages, churning statuses [20], or
viral suppression without treatment [21,22].
Figure 1 summarizes the model states and transitions,
including the annual probabilities used in the simulations.
The simulation structure and parameters used in this
simulation were generated and selected primarily to aid
conceptual and visual clarity for the demonstration
purposes. While we believe them to be broadly plausible,
they do not necessarily represent any specific populations,
country, or time period.
Scenarios
We generated two separate simulation scenarios: a
baseline (relatively low) and a high mortality scenario.
The baseline mortality scenario was designed to
demonstrate how the main continuum metrics respond
to conditions even without substantial mortality, while
the high mortality scenario demonstrates the additional
complications that occur with increased mortality when
people are removed from cross-sectional metrics due to
death, a competing event.
Each scenario had three periods, each 5 years long: a low
ART period, a normal ART period, and a second low
ART period. In Period 1, the ART initiation rate (0.05
per year) was set to be 1/10th the baseline rate. In Period
2, we increased the ART initiation rate (0.50 per year) to
represent introduction of wide scale ART availability. In
Period 3, we returned to the lower ART initiation rate
(0.05 per year). This last period may conceptually
represent a supply shortage or reversion to prior policies.
In all periods, mortality rates before viral suppression
were twice that as after viral suppression.
Additional model runs with slightly altered parameters
were generated on an ad-hoc basis to test the sensitivity of
model outcomes to parameter changes, including
modifying the mortality rate, viral suppression rate, and
period lengths.
Continuum metrics
For each scenario we compared two sets of different
continuum metrics from the simulated data first, cross-
sectional continuum metrics based on the UNAIDS 90–
90–90 targets; and second, stage-by-stage longitudinal
continuum metrics analogous to the UNAIDS targets.
Stage entry and completion events are the events that
define the denominator and numerator of a given
metric, respectively.
UNAIDS 90–90–90 metrics
The UNAIDS 90–90–90 metrics were based on cross-
sectional proportions. The denominator for each of the
three stages was the number of people who were alive and
had completed the entry event by the measurement date,
and the numerator was the number of people who were
alive and had completed both the stage entry and stage
completion event by the measurement date. This yielded
three probabilities on each date: the proportion of people
who knew their status out of those who were living with
HIV; the proportion of people who had initiated ART
out of those who had been diagnosed and were alive; and
the proportion of people who were virally suppressed out
of those who had initiated ART and were alive.
Longitudinal 90–90–90 metrics
The longitudinal 90–90–90 metrics measured the flow of
people as they passed between stages. We used Kaplan–
Meier curves [23] to estimate the cumulative incidence of
a stage completion event, where day 0 was the day on
which the stage entry event occurred. Individuals who
had not transitioned into a subsequent stage by the last
date of the measurement period were right censored on
that date. Death was considered a failure to achieve the
completion event (a competing event) rather than a
censoring event. As such, people who had died remained
in the ‘at-risk’ population to reflect that they died before
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Fig. 1. Diagram of Markov states and transitions. Pictured transition probabilities are annual transition probabilities for each
Markov state, and were converted to daily probabilities using the formula: Pdaily ¼ Pannualð Þ1=365.
transitioning, avoiding the issue of death inflating the
probability of transitioning to subsequent stages. This
approach is effectively equivalent to the Aalen–Johnson
cumulative incidence function in the presence of the
competing risk of death, given that they are strictly
hierarchical and censoring occurs for both potential risks
at the same time [24,25].
Estimates for each stage were restricted to persons who
completed the stage entry event within 2 years prior to
the measurement date; thus, the time-horizon of
measurement was up to 2 years from the stage entry
event to the stage exit event. For example, the
longitudinal continuum metrics for the transition
between knowing status and initiating ART at the end
of year 5 would consider only those individuals who
learned their status for the first time in years 4 or 5,
include only ART initiation events occurring before the
end of year 5, and would censor individuals who were
alive but had not yet initiated ART by the end of year 5.
As a result, the longitudinal continuum metrics in this
analysis do not reflect events that occur more than 2 years
from the stage entry event.
Analysis
The state of each cascade was measured and given at the
last day of each simulated year. For the UNAIDS 90–90–
90 metrics, this was the cross-sectional status of the
continuum, or a repeated cross-section similar to the
approach of Nosyk et al. [26]. For the longitudinal
metrics, these were the cumulative incidence curves for
each of the three transitions from the 2 years prior to the
last day of each simulated year.
All analyses were performed in R v3.6.1 [27]. The
longitudinal continuum metrics were generated using the
longitudinalcascade package, v0.3.2.1 [28], which was
developed by the first author for public use prior to this
simulation study. All code and simulated data are included
as supplements to this article.
Results
Total population proportions from the simulation are
shown in Appendix 1, http://links.lww.com/QAD/
B684 and Appendix 2, http://links.lww.com/QAD/




The cross-sectional UNAIDS 90–90–90 metrics are
shown as a series of annual, end-of-year cross-sections for
years 4–12 of the simulation in Fig. 2, with numerical
values in Appendix 3, http://links.lww.com/QAD/B684.
The top row shows the first of the three UNAIDS 90–
90–90 metrics: the percentage of persons living with HIV
who know their status out of those who are alive and
living with HIV. This proportion rose slowly over time in
all periods, reflecting the steady accumulation of HIV
diagnoses via the constant HIV diagnosis rate against a
background where the mortality rate was lower than the
HIV incidence rate.
The proportion of those who are on ARTof those who
know their status was slow to respond to the changes in
ART initiation probabilities between model periods, as
seen in the second row of Fig. 2. At the end of year 5,
only 4% of people who knew their status were on ART,
reflecting the very low probability of any diagnosed
individual initiating ART. Once ART rates were raised
to ‘normal’ levels, the proportion who were on ART
jumped to 27% at the end of year 6, reflecting rapid
uptake from the backlog of individuals built up by this
point who knew their status but had not yet initiated
ART. The proportion of individuals who had initiated
ART increased steadily to 58% at the end of year 10, but
then decreased only slowly in Period 3 despite the rapid
drop in ART initiation probabilities at the start of
year 11.
The proportion of people who have become virally
suppressed out of those who have initiated ART appears
in the bottom row of Fig. 2. The initial dip in the
proportion who have achieved viral suppression in year 6,
when ART roll-out began, was largely caused by
improving conditions in other periods; as more people
initiated ART, the denominator grew, and it took time for
the numerator to catch up. Despite no change in the viral
suppression rate after ART initiation, the dip in year 6
leads to the impression that viral suppression was a
substantial bottleneck in the continuum at that time. That
impression could lead to erroneous conclusions, such as
‘the people being reached with expanded ART access
have worse adherence than those who were initiated ART
in prior periods’ or ‘adherence counselling should be
prioritized for funding.’ As Period 2 continued, the
proportion of people who were virally suppressed
continued to increase as this initial influx people who
had initiated ART subsequently achieved viral suppres-
sion, again despite no actual changes in the viral
suppression rate among those who are on ART.
The comparable chart for the longitudinal 90–90–90
metrics is shown in Fig. 3. Each row reflects the
cumulative incidence function for the transition from one
stage to the next over the prior 2 years, rather than the
total accumulation of people who have reached each stage
to date. Because the cumulative incidence function is
determined almost exclusively by the transition proba-
bilities corresponding to each stage, the first and last rows
of the longitudinal 90–90–90 continuum remain
virtually unchanged over time, reflecting the fact that
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the underlying rates of HIV acquisition, learning status,
and viral suppression remained constant throughout
the simulation.
Just as the top and bottom rows of Fig. 3 properly reflect
the constant transition probabilities underlying their
corresponding metrics, the middle row properly captures
the changing probability of ART initiation across calendar
periods. The response to the changing ART initiation
probabilities was nearly immediate. This feature of the
longitudinal continuum is largely due to its explicit
consideration of only recent transitions from stage to
stage, as opposed to a cross-sectional metric that reflects
prevalence arising from transitions that had occurred at
any point in the past.
The longitudinal metrics also yield some additional
insight in the form of person-time. The cross-sectional
metrics showed relatively high prevalence of being on
ART and being virally suppressed at the end of Period 2,
seemingly suggesting relatively high rates of ART
initiation and viral suppression. These cross-sectional
metrics would have continued to increase had the ‘normal
ART’ conditions persisted, reaching the full UNAIDS
90–90–90 targets despite no improvements in health
systems performance after the switch to higher ART
initiation probabilities at the start of year 6. However, the
longitudinal metrics reveal a large amount of person-time
between those transitions, reflecting the time in which
individuals remained virally unsuppressed and highlight-
ing the remaining gaps for intervention.
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Fig. 2. UNAIDS 90–90–90 metrics. This chart shows the results of the cross-sectional UNAIDS 90–90–90 metrics at the end of
years 4–12 of the simulation. Each row represents one of the three UNAIDS 90–90–90 metrics, where the background colour
indicates the stage for the denominator, and the bars represent the metric. The main bars (demarcated by solid lines) represent the
normal mortality scenario, while the dotted lines represent the results for the high mortality scenario. The areas in the high
mortality scenario are left transparent to increase readability and comparison with the low mortality scenario.
High mortality scenario
Increasing mortality had a complex and potentially
counterintuitive impact on the health systems perfor-
mance implied by the UNAIDS 90–90–90 metrics, as
shown in the dotted lines in Fig. 2. The UNAIDS 90–
90–90 metrics were largely unresponsive to the five-fold
increase in the annual mortality rate. In the case of the first
and second components, we observe implied overall
decreases in health systems performance. However, the
third component appears to imply improved health systems
performance with higher mortality. The reason for this
observed increase in viral suppression is that a higher
proportion of people were dying and being removed from
the denominator as compared with the low mortality
scenario. Additional sensitivity tests show that this effect is
exacerbated when the mortality rate is increased and/or
when the viral suppression rate is reduced.
The longitudinal 90–90–90 metrics resulted in unam-
biguous decline in the measurements of health systems
performance of all stages when mortality increased, as
shown in Fig. 3. The proportion of people who had died
before transitioning into the next stage is shown in the red
area at the top of each panel, which is visually larger for all
previral suppression stages in the continuum under the
high mortality scenario. Furthermore, higher mortality
also results in an unambiguous reduction in the
proportion of people transitioning into the next stage
for all three metrics. The nonambiguity of mortality in
the longitudinal 90–90–90 metrics is due to people
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Fig. 3. Longitudinal 90–90–90 metrics. Longitudinal 90–90–90 metrics calculated at the end of years 4–12 of the simulation.
Each row represents one of the three cumulative incidence curves in the longitudinal continuum, where the background colour
indicates the stage for the denominator. The main filled curves (demarcated by the solid lines) represent the normal mortality
scenario, while the dotted lines represent the results for the high mortality scenario. The areas corresponding to differences
between the low and high mortality scenarios are left transparent for readability and comparison with the low mortality scenario.
remaining in the denominator even after dying, as death
was treated as a failure to achieve an even through the
competing risk of death rather than failure to observe an
event (censoring).
Discussion
Metrics used to evaluate health systems performance
should be highly responsive to and reflective of current
conditions, independently identify performance between
stages, and avoid implying higher performance in
scenarios with poorer outcomes. The longitudinal
continuum metrics perform better than the UNAIDS
90–90–90 metrics on all three of these criteria in our
simulation. The cross-sectional UNAIDS 90–90–90
metrics were relatively slow to respond to changes,
reflected changes in stage transition rates other than the
primary stage transition event under study, and implied
improvements in health systems performance under
higher mortality rates. By contrast, the longitudinal
continuum was quick to respond, maintained relative
independence in reflecting stage transitions, and unam-
biguously indicated lower performance with higher
mortality.
Although we used a simplistic model, more realistic
conditions would not resolve the issues with the
UNAIDS 90–90–90 illustrated here. Perhaps the least
realistic aspect of our simulation was having discrete
periods with sharp discontinuities instead of gradual
changes over time. A more realistic simulation could
incorporate demographics, viral load, disease stage, and
different propensities for moving through the continuum
according to these factors. Further, the longitudinal
continuum model itself could be made more complex
with skipped and out-of-order transitions, ‘churn’ in and
out of states of care retention and viral suppression
[10,20,29], and/or ‘side doors’ [19]. While these nuances
are important to include and integrate into performance
metrics in real-world settings, we have no reason to
believe that simulating them would have any notable
impact on the qualitative conclusions from this study.
The simplicity of implementing the UNAIDS 90–90–
90 metrics belies their complex and potentially
misleading interpretations when used as health systems
performance indicators. Describing the current status of
the HIV care continuum with cross-sectional measures
can obscure how past periods impacted the current cross-
section. Repeated cross-sectional data over time can help
improve inference by hinting at transition rate changes,
but still necessitates sophisticated understanding and
modelling of population dynamics, as seen in comparing
cross-sectional and longitudinal metrics using real world
data over the ART roll out in KwaZulu-Natal, South
Africa [4].
While the longitudinal metrics proposed here are better
able to evaluate current systems performance by directly
reflecting transition times, they also have tradeoffs. First,
they require large and sustained investment in data
collection, cleaning, and analysis efforts which are
difficult to achieve at scale [30,31] and may be limited
to particular geographic regions. In the case of the first
metric, determining the date of the stage HIVacquisition,
data collection would require frequent repeated testing of
a representative population. Second, longitudinal metrics
require more complicated analysis and interpretation
because they include time. This potential limitation can
be mitigated or eliminated by choosing easily interpret-
able metrics, as discussed below, and/or standardizing
analysis methods. Third, longitudinal metrics do not
necessarily capture all relevant time horizons. In the
example we present in this article, the 2-year data
collection and time horizon inherently ignores persons
whose transition times exceed longitudinal time hor-
izons. This issue can be mitigated by extending the stage
eligibility period, at the cost of the results being less
specific to recent conditions.
Target setting using the longitudinal continuum metrics
can be as simple as adding a ‘within X time’ component to
existing percentage goals, provided appropriate time
thresholds [32]. More comprehensive targets could utilize
area under the survival curve, or restricted mean survival
time [33] metrics. Alternatively, targets can be measured
along the reverse axis and measure median or other
percentile time to transition, noting that these percentiles
may never be reached in many cases. Longitudinal
continuum metrics may also include loss of person-time
due to churning states, depending on how they
are defined.
We recommend utilizing a hybrid of longitudinal and
cross-sectional continuum metrics for health systems
evaluation and target setting. Setting precise definitions
and presentation style for international agendas requires
coordination between a diverse set of stakeholders, but a
plausible example set of targets could leverage the best and
most practical aspects of both. The first two metrics might
be cross-sectional targets based on the population living
with HIV: 90% of people who are living with HIV should
be diagnosed and engaged with care; and at least 73% of
people who are living with HIV should be virally
suppressed. Although these two targets are likely to be
relatively unresponsive in real time, they do not run the
risk of issues related to between-stage denominator
interactions over time that impact current UNAIDS 90–
90–90 metrics. The second target collapses the original
90–90–90 to directly assess its original purpose: keeping
viral suppression sufficiently high to dampen spread of
HIV. In addition, two longitudinal targets could replace
the latter two targets in the current UNAIDS 90–90–90.
In keeping with the ‘90–90–90’ theme: 90% of people
who are newly linked to care should be on ARTwithin 90
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days of linking to care, and 90% of people who are newly
on ART should be virally suppressed within 90 days of
starting ART. These two longitudinal measures allow
stage-specific assessments of health systems performance.
We strongly recommend that existing cross-sectional
continuum measurements be viewed with a critical
understanding of their limitations, and that longitudinal
metrics be incorporated in evaluation of progress and
decision-making around HIV policies and strategies
wherever possible. We further recommend that major
funders invest in systematic data collection efforts to allow
longitudinal analysis and calculation of longitudinal care
continuum metrics, including expanding existing
regional cohort data, introducing new longitudinal
HIV monitoring efforts, coordinating across existing
monitoring efforts, and expanding and incorporating
clinical data networks [34].
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